Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omilancor (BT-11) in Moderate to Severe Crohn's Disease
NCT03870334Phase 2Terminated
- Sponsor
- NImmune Biopharma
- Start
- May 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omilancor in Crohn's disease, sponsored by NImmune Biopharma. Started May 2021; status: terminated.
02
Drugs
omilancor
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03870334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03870334.